Acute disseminated encephalomyelitis (ADEM) following recent Oxford/AstraZeneca COVID-19 vaccination.
Forensic Sci Med Pathol
; 18(1): 74-79, 2022 03.
Article
in En
| MEDLINE
| ID: mdl-34735684
This report describes the clinical context and autopsy findings in the first reported fatal case of acute disseminated encephalomyelitis (ADEM), developed after being vaccinated using the Oxford/AstraZeneca COVID-19 vaccine. ADEM is a rare autoimmune disease, causing demyelination in the brain and spinal cord. A wide variety of precipitating factors can trigger ADEM, and it has long been known to be a rare adverse event following some types of vaccinations. Recently, ADEM has also been associated with COVID-19 infection and (very rarely) with COVID-19 vaccination. The reports of the latter however all pertain to living patients. Our case demonstrates that ADEM should be considered in patients developing neurological symptoms post COVID-19 vaccination, although that this adverse reaction is likely to remain extremely rare. Our report further emphasizes the added value of comprehensive post mortem investigation to confirm ante mortem diagnosis and to determine vaccination safety.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Encephalomyelitis, Acute Disseminated
/
COVID-19
Type of study:
Diagnostic_studies
/
Etiology_studies
Limits:
Humans
Language:
En
Journal:
Forensic Sci Med Pathol
Journal subject:
JURISPRUDENCIA
/
MEDICINA
/
PATOLOGIA
Year:
2022
Document type:
Article
Affiliation country:
Australia
Country of publication:
United States